Back

Impact of ferric carboxymaltose therapy on renal function in patients with chronic heart failure and anemia

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Complex comorbidities and heart failure Comorbidities HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Giuseppe Armentaro

University Hospital Renato Dulbecco, Catanzaro (Italy)

4 More presentations in this session

Presentation thumbnail
Clinical course of atrial fibrillation patients with and without history of takotsubo syndrome: a propensity matched analysis from the GEIST and ATHERO-AF registries
Doctor L. Arcari (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Elderly satelia surveillance in heart failure (ElderSAT-HF): predictive factors of events after discharge of cardiogeriatric unit
Doctor R. Esser (Versailles, FR)
Abstract Slides Video
Presentation thumbnail
Unravelling the ugly truth about sleep apnea and advanced heart failure: a real-world setting
Doctor P. Bernardes (Setubal, PT)
Abstract Slides Video
Presentation thumbnail
A formidable combination: chronic kidney disease and the under-prescription of guideline directed medical therapy for heart failure
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Complex comorbidities and heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on renal function and cardiovascular outcomes in heart failure: Korean heart failure III registry
thumbnail
Congress Presentation
Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection
thumbnail
Congress Presentation
Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources